Zentalis Pharmaceuticals, Inc. has entered into an exclusive license agreement with Immunome, Inc. for a preclinical antibody-drug conjugate (ADC) and proprietary ADC platform technology, receiving an up-front payment of $35 million in cash and stock, with potential milestone payments and royalties.